

Ascendis Health Limited
(Registration number 2008/005856/06)
(Incorporated in the Republic of South Africa)
Share code: ASC
ISIN: ZAE000185005
("Ascendis Health" or "the Company")



TERMINATION OF THE MEDICAL DISPOSAL, WITHDRAWAL OF CAUTIONARY ANNOUNCEMENT IN RESPECT OF THE MEDICAL DISPOSAL AND RENEWAL OF CAUTIONARY IN RESPECT OF THE AUSTELL PHARMA TRANSACTION

Shareholders are referred to the announcement published on SENS on 1 February 2022, wherein shareholders were, *inter alia*, advised that Ascendis Health SA Holdings Proprietary Limited ("A~~H~~S~~A~~"), a wholly owned subsidiary of Ascendis Health, had concluded an agreement with Apex Management Services Proprietary Limited ("A~~p~~e~~x~~"), in terms of which A~~H~~S~~A~~ would dispose of its entire interest in each of The Scientific Group Proprietary Limited, Surgical Innovations Proprietary Limited ("S~~I~~") and through the sale of S~~I~~, Ortho-Xact Proprietary Limited, a subsidiary of S~~I~~, being the legal entities through which Ascendis Medical operates (the "Medical Disposal").

Shareholders are advised that the Medical Disposal has been terminated by mutual agreement between the parties.

WITHDRAWAL OF CAUTIONARY ANNOUNCEMENT IN RESPECT OF THE MEDICAL DISPOSAL

Following the termination of the Medical Disposal, A~~H~~S~~A~~ will no longer be disposing of the majority of its assets by way of a "series of transactions" for purposes of section 112(3)(b) of the Companies Act, 71 of 2008. Accordingly, Shareholders are no longer required to exercise caution when dealing in Ascendis securities in respect of the Medical Disposal.

RENEWAL OF CAUTIONARY ANNOUNCEMENT IN RESEPECT OF THE AUSTELL PHARMA TRANSACTION

Shareholders are referred to the cautionary announcement published on SENS on 16 May 2022 and the further cautionary announcement published on SENS on 17 May 2022. Shareholders are advised to continue to exercise caution when dealing in Ascendis securities until such time as there is clarity as to whether an agreement in respect of the disposal of the Pharma business unit to Austell Pharmaceuticals Proprietary Limited may be concluded.

RESPONSIBILITY STATEMENT

The board of directors of the Company (the "Board") accepts responsibility for the information contained in this announcement as it pertains to Ascendis Health. To the best of the Board's knowledge and belief, the information contained in this announcement as it pertains to Ascendis Health is true and nothing has been omitted which is likely to affect the importance of such information.

27 June 2022

Bryanston

Sponsor



Questco Corporate Advisory Proprietary Limited